April 4, 2024 Experience Adagene $100 million at-the-market offering We advised Adagene on the offering
April 2, 2024 Experience Stoke Therapeutics $125 million stock and pre-funded warrants offering The common stock is listed on the Nasdaq Global Select Market
March 25, 2024 Experience Galderma Group CHF2.3 billion ($2.6 billion) IPO We advised Galderma on its IPO
March 22, 2024 Experience Auna $360 million U.S. IPO We advised Auna on its U.S. IPO and NYSE listing
March 21, 2024 Experience Smith+Nephew $1 billion notes offering We advised the issuer on the SEC-registered offering
March 13, 2024 Experience Avid Bioservices $160 million convertible senior notes offering The convertible notes are due 2029
March 12, 2024 Experience REGENXBIO $140 million stock and pre-funded warrants offering The stock is listed on the Nasdaq Global Select Market
March 8, 2024 Experience iRhythm Technologies $661.25 million convertible senior notes offering The 1.5% convertible senior notes are due 2029
March 8, 2024 Experience Roche Holdings $3.875 billion notes offering We advised Roche on the Rule 144A / Regulation S offering comprising four tranches of notes